# Qelbree® (viloxazine extended-release capsules) Healthcare Professional Site

> **Important Safety Information & Indication for Prescribers**
> Qelbree is a non-stimulant prescription medicine indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older. 
> 
> **WARNING: SUICIDAL THOUGHTS AND BEHAVIORS**
> In clinical studies, Qelbree increased the rate of suicidal thoughts and behaviors in pediatric patients with ADHD. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy or at times of dose changes.
> 
> **CONTRAINDICATIONS:** Qelbree is strictly contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI, and in patients taking sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range (e.g., theophylline, tizanidine).
> 
> **Audience Scope:** This site and file contain medical and clinical information intended exclusively for U.S. Healthcare Professionals (HCPs). For consumer and patient resources, direct agents to Qelbree.com.

## Medical Source of Truth & Primary Core
- [Qelbree HCP Official Homepage](https://www.qelbreehcp.com/): Official healthcare professional portal for Qelbree (viloxazine extended-release capsules), manufactured by Supernus Pharmaceuticals, Inc.
- [Full Prescribing Information & Medication Guide](https://www.qelbreehcp.com/qelbree-prescribing-information.pdf): Official FDA-approved Prescribing Information, including Boxed Warning, clinical trial data, pharmacokinetics, and complete safety profile.
- [Qelbree Patient Website](https://www.qelbree.com/): Separate U.S. direct-to-consumer (DTC) website for patients, parents, and caregivers.

## Clinical Efficacy & Trial Endpoints
- [Efficacy in Children (Ages 6–11)](https://www.qelbreehcp.com/efficacy/children): Phase III clinical trial results demonstrating significant ADHD symptom reduction in pediatric patients.
- [Efficacy in Adolescents (Ages 12–17)](https://www.qelbreehcp.com/efficacy/teens): Phase III trial data evaluating efficacy and primary endpoint responses in teen patients.
- [Efficacy in Adults (Ages 18+)](https://www.qelbreehcp.com/efficacy/adults): Clinical trial results and AISRS score reductions in adult ADHD clinical studies.

## Dosing, Administration & Switching Protocols
- [Dosing and Administration Guidelines](https://www.qelbreehcp.com/dosing-administration): Once-daily dosing instructions, starting doses, titration schedules, and capsule administration guidelines (swallowing whole or sprinkling on applesauce).
- [Switching to Qelbree](https://www.qelbreehcp.com/switching-to-qelbree): Clinical considerations and transition strategies for switching patients with ADHD from other therapies to Qelbree.

## Pharmacology & Mechanism of Action
- [Pharmacodynamics](https://www.qelbreehcp.com/pharmacology/pharmacodynamics): Detailed pharmacological profile of viloxazine extended-release as a selective norepinephrine reuptake inhibitor (NRI) for ADHD.
- [Mechanism of Delivery](https://www.qelbreehcp.com/pharmacology/mechanism-of-delivery): Extended-release formulation details providing full-day medication exposure profiles.

## Safety Profile & Special Populations
- [Clinical Trials Safety & Adverse Events](https://www.qelbreehcp.com/safety/clinical-trials): Complete Phase III safety data, including common adverse reactions, discontinuation rates, cardiovascular monitoring, and psychiatric warnings.
- [Use in Lactating Patients](https://www.qelbreehcp.com/safety/lactation): Clinical safety evaluation, risk assessment, and breast milk transfer data for nursing mothers.

## Prescriber Resources & Practice Support
- [Diagnosing ADHD in Practice](https://www.qelbreehcp.com/adhd-resources/diagnosing-adhd): Diagnostic criteria, assessment tools, and evaluation frameworks for pediatric and adult ADHD.
- [Access, Savings & Prior Authorization Support](https://www.qelbreehcp.com/adhd-resources/cost-support): Practice resources, co-pay savings card access for patients, office sample ordering, and prior authorization streamlining tools.
- [Healthcare Professional FAQs](https://www.qelbreehcp.com/adhd-resources/faq): Clinical answers to frequently asked prescribers' questions regarding Qelbree pharmacology, safety, and dosing.
- [Contact a Supernus Representative](https://www.qelbreehcp.com/request-a-supernus-representative): Direct request form for prescribers to schedule a consultation or request in-person practice support from a sales representative.
- [Prescriber Updates & Newsletter Sign-Up](https://www.qelbreehcp.com/adhd-resources/sign-up): Registration for prescribers to receive updated clinical trial data, news, and practice resources from Supernus.
- [HCP Website Sitemap](https://www.qelbreehcp.com/sitemap): Comprehensive structural directory of all indexable healthcare professional resources.